CytomX Therapeutics (CTMX) Change in Account Payables (2014 - 2026)
CytomX Therapeutics (CTMX) posted Change in Account Payables of $67000.0 for Q1 2026, down 89.77% on a QoQ basis from $655000.0 in Q4 2025, and up 108.33% year-over-year from $32160.0 in Q1 2025.
CytomX Therapeutics (CTMX) Change in Account Payables (2014 - 2026) Analysis & Trends
CytomX Therapeutics' Change in Account Payables history runs 13 years deep, the most recent figure standing at $67000.0 for Q1 2026.
- Quarterly Change in Account Payables rose 108.33% year-over-year to $67000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 164.92% YoY) and the FY2025 annual result came in at $221000.0, up 174.41% from the prior year.
- Change in Account Payables was $67000.0 for Q1 2026 at CytomX Therapeutics, down from $655000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $3.3 million in Q3 2022 and bottomed at -$2.4 million in Q4 2022.
- A 5-year average of -$80411.8 and a median of -$49000.0 in 2025 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables surged 1875.68% — and 2023, when it tumbled 635.19%.
- CytomX Therapeutics' Change in Account Payables stood at -$2.4 million in 2022, then surged by 86.18% to -$328000.0 in 2023, then increased by 20.43% to -$261000.0 in 2024, then jumped by 350.96% to $655000.0 in 2025, then tumbled by 89.77% to $67000.0 in 2026.
- Business Quant data shows CTMX's Change in Account Payables at $67000.0 in Q1 2026, $655000.0 in Q4 2025, and $419000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 16.86 Mn |
| 10 | CytomX Therapeutics | 574.36 Mn | 227.66 Mn | - | 67,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67,000.00 |
| Mar 31, 2026 | 67,000.00 |
| Dec 31, 2025 | 655,000.00 |
| Dec 31, 2025 | 655,000.00 |
| Sep 30, 2025 | 419,000.00 |
| Sep 30, 2025 | 419,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Mar 31, 2025 | -804,000.00 |
| Mar 31, 2025 | -804,000.00 |
| Dec 31, 2024 | -261,000.00 |
| Dec 31, 2024 | -261,000.00 |
| Sep 30, 2024 | 811,000.00 |
| Sep 30, 2024 | 811,000.00 |
| Jun 30, 2024 | -1.43 Mn |
| Jun 30, 2024 | -1.43 Mn |
| Mar 31, 2024 | 581,000.00 |
| Mar 31, 2024 | 581,000.00 |
| Dec 31, 2023 | -328,000.00 |
| Dec 31, 2023 | -328,000.00 |